MERCK ANNOUNCES PHASE 3 KEYNOTE-B96 TRIAL MET SECONDARY ENDPOINT OF OVERALL SURVIVAL (OS) IN ALL COMERS POPULATION OF PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER

Reuters · 10/16/2025 10:45

Please log in to view news